854111-49-2

Usage

Uses

Used in Pharmaceutical Applications:
(Z,Z)-5-[3-chloro-4-((2S)-2,3-dihydroxypropoxy)benzylidene]-2-propylimino-3-o-tolyl-thiazolidin-4-one is used as a pharmaceutical compound for its antifungal, antibacterial, and anticancer properties. Its diverse therapeutic potential makes it a promising candidate for the development of novel drugs to combat various diseases.
Used in Anticancer Applications:
In the field of oncology, (Z,Z)-5-[3-chloro-4-((2S)-2,3-dihydroxypropoxy)benzylidene]-2-propylimino-3-o-tolyl-thiazolidin-4-one is used as an anticancer agent. It has shown potential in targeting and inhibiting the growth of cancer cells, making it a valuable asset in the fight against various types of cancer.
Used in Treatment of Diabetes:
(Z,Z)-5-[3-chloro-4-((2S)-2,3-dihydroxypropoxy)benzylidene]-2-propylimino-3-o-tolyl-thiazolidin-4-one is used as a therapeutic agent for diabetes. Its potential in managing and treating diabetes-related conditions offers hope for the development of new treatments to improve the quality of life for patients with diabetes.
Used in Treatment of Neurodegenerative Diseases:
In the field of neurology, (Z,Z)-5-[3-chloro-4-((2S)-2,3-dihydroxypropoxy)benzylidene]-2-propylimino-3-o-tolyl-thiazolidin-4-one is used as a potential treatment for neurodegenerative diseases. Its ability to target and alleviate the symptoms of such conditions makes it a promising compound for further research and development in this area.
Used in the Chemical Industry:
(Z,Z)-5-[3-chloro-4-((2S)-2,3-dihydroxypropoxy)benzylidene]-2-propylimino-3-o-tolyl-thiazolidin-4-one is used as a chemical intermediate for the synthesis of various compounds with potential applications in different industries, including pharmaceuticals, agrochemicals, and materials science. Its unique structure and properties make it a valuable building block for the development of new molecules with specific functions and uses.

Upstream product

• 75105-08-7 C₁₁H₁₆N₂S 
• 614-69-7 2-tolyl isothiocyanate 
• 2420-16-8 4-hydroxy-3-chlorobenzaldehyde 
• 854107-53-2 (Z)-2-propylimino-3-(2-methylphenyl)thiazolidin-4-one 
• 1563017-36-6 (R)-3-chloro-4-(2,3-dihydroxypropoxy)benzaldehyde 
• 1029435-58-2 (2Z,5Z)-5-[(3-chloro-4-hydroxyphenyl)methylene]-3-(o-tolyl)-2-propyliminothiazolidin-4-one 
• 57090-45-6 (2R)-3-chloro-1,2-propanediol 
• 854107-54-3 3-chloro-4-((4R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethoxy)benzaldehyde 
• 854107-60-1 4-(2,3-dihydroxypropoxy)-3-chlorobenzaldehyde 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF|(2Z,5Z)-5-(3-CHLORO-4-((R)-2,3-DIHYDROXYPROPOXY)BENZYLIDENE)-2-(PROPYLIMINO)-3-|(O-TOLYL)THIAZOLIDIN-4-ONE AND INTERMEDIATE USED IN SAID PROCESS

The present invention relates to a new process for the preparation of (2Z,5Z)-5-(3-chloro-4- ((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one and to the new intermediate (R)-3-chloro-4-(2,3-dihydroxypropoxy)-benzaldehyde used in this process. (2Z,5Z)-5-(3-Chloro-4-((R)-2,3-dihydroxypropoxy)benzylidene)-2-(propylimino)-3- (o-tolyl)thiazolidin-4-one is described in WO 2005/054215 to act as an immunosuppressive agent. The present invention further also relates to a new process for the preparation of (R)-3-chloro-4-(2,3-dihydroxypropoxy)-benzaldehyde.

2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P 1 receptor agonists

Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P conveys its activity through five specific G-protein coupled receptors numbered S1P1 through S1P5. Agonists of the S1P1 receptor block the egress of T-lymphocytes from thymus and lymphoid organs and hold promise for the oral treatment of autoimmune disorders. Here, we report on the discovery and detailed structure-activity relationships of a novel class of S1P1 receptor agonists based on the 2-imino-thiazolidin-4-one scaffold. Compound 8bo (ACT-128800) emerged from this series and is a potent, selective, and orally active S1P1 receptor agonist selected for clinical development. In the rat, maximal reduction of circulating lymphocytes was reached at a dose of 3 mg/kg. The duration of lymphocyte sequestration was dose dependent. At a dose of 100 mg/kg, the effect on lymphocyte counts was fully reversible within less than 36 h. Pharmacokinetic investigation of 8bo in beagle dogs suggests that the compound is suitable for once daily dosing in humans.

5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS

The invention relates to pharmaceutical compositions containing at least one 5- (benz- (Z) -ylidene-thiazolidin-4-one derivative (I), to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thi